Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

Products from BPS Bioscience require a minimum order value above 400€

Application: Screen neutralizing antibodies against the SARS-CoV-2 BA.4/5 variant in ACE2-HEK293 cells

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants have been divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. Among them, BA.4 and BA.5 have identical mutations on their spike protein. The spike protein of BA.4 and BA.5 are referred as BA.4/5 in this datasheet.The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 BA.4/5 Variant Spike (Genbank Accession #QHD43416.1 containing all the BA.4/5 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the eGFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 BA.4/5 variant in a Biosafety Level 2 facility.As shown in Figure 2, the Spike Omicron BA.4/5 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.4/5 Variant:Del69-70, T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K

Formulation: The lentiviruses were produced from HEK293T cells. Supplied in medium containing 90% DMEM + 10% FBS.

Storage Stability: Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C. 

Supplied As: The titer will vary with each lot; the exact value is provided with each shipment.

Warnings: Avoid freeze/thaw cycles.

Biosafety Level: BSL-2

• Artikelnummer: BPS78652-1
• Hersteller: BPS Bioscience
• Hersteller Artikelnummer: 78652-1
• Verpackungseinheit: 100 µl
• Mengeneinheit: STK